Literature DB >> 2123119

The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET.

D J Brooks1, E P Salmon, C J Mathias, N Quinn, K L Leenders, R Bannister, C D Marsden, R S Frackowiak.   

Abstract

18F-dopa and S-11C-nomifensine (NMF) are positron emitting tracers whose caudate and putamen uptake reflects striatal dopamine storage capacity and the integrity of dopamine reuptake sites, respectively. Using these two tracers, the integrity of the presynaptic striatal dopaminergic system has been studied with positron emission tomography (PET) in 10 subjects with multiple system atrophy (MSA, Shy-Drager syndrome) who had an akinetic-rigid syndrome that was poorly responsive to L-dopa, autonomic failure, and cerebellar ataxia. PET findings for the 10 MSA patients were compared with those for 13 age-matched controls, 8 subjects with L-dopa responsive Parkinson's disease (PD), and 7 subjects with pure autonomic failure (PAF). Influx constants, Ki, reflecting specific 18F-dopa uptake into striatal tissue, were severely reduced in the putamen and caudate of the 10 MSA subjects (mean putamen Ki 0.005 min-1 MSA vs 0.013 min-1 controls; mean caudate Ki 0.007 min-1 MSA vs 0.013 min-1 controls). Reduction of putamen, but not caudate, 18F-dopa uptake correlated with severity and duration of locomotor disability. Eight patients with PD, and a similar degree and duration of locomotor disability to the patients with MSA, demonstrated equal impairment of mean putamen 18F-dopa uptake, but significant preservation of mean caudate function. The 7 PAF patients had normal mean levels of putamen and caudate 18F-dopa uptake, although 1 individual PAF patient had significantly impaired striatal function. The MSA and PD groups of subjects both showed significantly reduced levels of specific striatal S-11C-NMF binding, again caudate function being relatively preserved in PD. It is concluded that in both MSA and PD there is a parallel decline of striatal dopamine storage capacity and reuptake site integrity, probably reflecting a loss of nigrostriatal nerve terminals. Caudate function is relatively preserved in PD compared with MSA. The majority of PAF patients have an intact nigrostriatal dopaminergic system, suggesting that PAF is a condition distinct from PD and MSA in spite of some pathological similarities. PET is capable of detecting subclinical nigrostriatal involvement in PAF patients when this is present.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2123119     DOI: 10.1093/brain/113.5.1539

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  44 in total

1.  Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.

Authors:  J O Rinne; H Ruottinen; J Bergman; M Haaparanta; P Sonninen; O Solin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-12       Impact factor: 10.154

2.  Comparative analysis of the gait disorder of normal pressure hydrocephalus and Parkinson's disease.

Authors:  H Stolze; J P Kuhtz-Buschbeck; H Drücke; K Jöhnk; M Illert; G Deuschl
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-03       Impact factor: 10.154

3.  A novel computer-assisted image analysis of [123I]β-CIT SPECT images improves the diagnostic accuracy of parkinsonian disorders.

Authors:  Georg Goebel; Klaus Seppi; Eveline Donnemiller; Boris Warwitz; Gregor K Wenning; Irene Virgolini; Werner Poewe; Christoph Scherfler
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-12-21       Impact factor: 9.236

Review 4.  The design of clinical trials for cell transplantation into the central nervous system.

Authors:  Pierre Cesaro
Journal:  NeuroRx       Date:  2004-10

Review 5.  Positron emission tomography imaging of transplant function.

Authors:  David J Brooks
Journal:  NeuroRx       Date:  2004-10

6.  Central dopamine deficiency in pure autonomic failure.

Authors:  David S Goldstein; Courtney Holmes; Takuya Sato; Miya Bernson; Neptune Mizrahi; Richard Imrich; Gilberto Carmona; Yehonatan Sharabi; Alexander O Vortmeyer
Journal:  Clin Auton Res       Date:  2008-04       Impact factor: 4.435

7.  Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.

Authors:  P K Morrish; J S Rakshi; D L Bailey; G V Sawle; D J Brooks
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-03       Impact factor: 10.154

8.  Reply: Does dominant pedunculopontine nucleus exist? Probably not.

Authors:  Brett W Fling; John G Nutt; Fay B Horak
Journal:  Brain       Date:  2014-11-02       Impact factor: 13.501

9.  Cognitive and SPECT characteristics predict progression of Parkinson's disease in newly diagnosed patients.

Authors:  Kathy Dujardin; Luc Defebvre; Alain Duhamel; Pascal Lecouffe; Pascal Rogelet; Marc Steinling; Alain Destée
Journal:  J Neurol       Date:  2004-11       Impact factor: 4.849

10.  Neuropsychological pattern of striatonigral degeneration: comparison with Parkinson's disease and progressive supranuclear palsy.

Authors:  B Pillon; N Gouider-Khouja; B Deweer; M Vidailhet; C Malapani; B Dubois; Y Agid
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.